# Alpha Tau Medical Ltd. (DRTS) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $13.54, market value $1.3 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Alpha Tau Medical Ltd. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 28.4×**. The shares trade at 28.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -2.6%** (5-yr avg -9.2%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -55.3%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -17.8%**. Earnings per share fell 17.8%.

## Financial health
- **Current ratio: 7.45** (quick 7.45). Current assets cover the next year's liabilities 7.45 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Alpha Tau Medical Ltd. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (5 analysts). 5 analysts cover Alpha Tau Medical Ltd.; the consensus is buy, with an average price target of $17.80 (+31% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 208.0%** (YTD 159.2%, 3-mo 7.6%). The shares are up 208.0% over twelve months including dividends.
- **From 52-week high: -14.2%** (294.8% above the low). Trading 14% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 41**. An RSI of 41 is neutral.
- **Beta (1 yr): 2.07** (volatility 77%). Beta of 2.07 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=DRTS · Page: https://foliofundamentals.com/stocks/drts

Not investment advice.